Today: 21 May 2026
Browse Category

NYSE:MRK 10 January 2026 - 21 January 2026

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
····
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Merck stock slips as FDA fast-track questions build and earnings near

Merck stock slips as FDA fast-track questions build and earnings near

Merck shares fell 1.2% to $109.65 Friday, underperforming the market as investors reacted to renewed scrutiny of the FDA’s expedited drug review program. The FDA delayed reviews of two drugs in the program after safety concerns, including a reported patient death. Merck is developing two drugs under this program and plans to report earnings on Feb. 3. About 7.6 million shares traded by the afternoon.
16 January 2026
··
Dow Jones Today: Dow slips as options expiry hits and investors weigh bank earnings

Dow Jones Today: Dow slips as options expiry hits and investors weigh bank earnings

The Dow Jones Industrial Average fell 70 points, or 0.14%, to 49,372.07 in early Friday trading as losses in healthcare and consumer stocks offset gains in tech. The S&P 500 edged up 0.07%, while the Nasdaq rose 0.26%. PNC Financial jumped 3.9% after reporting a 25% profit increase. Options expiration and muted volatility kept traders cautious near record highs.
16 January 2026
········
Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck shares fell 0.2% to $110.75 Thursday after the FDA delayed decisions in its new voucher fast-track program, according to Reuters. The FDA postponed reviews of drugs from Sanofi, Disc Medicine, and Eli Lilly, citing safety concerns. Investors are watching for Merck’s Feb. 3 earnings and updates on its drug pipeline. Healthcare stocks broadly declined, with Eli Lilly down 3.6%.
15 January 2026
···
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck shares closed up 2.54% at $111.01 Wednesday, outperforming a falling U.S. market. Management raised forecasts for new drugs, projecting $70 billion in revenue from growth drivers by the mid-2030s. CEO Rob Davis said Merck has capacity for major deals and is running 80 phase three trials. Investors are watching for Feb. 3 earnings to assess the 2026 outlook.
15 January 2026
···
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck raised its long-term revenue forecast for new products to $70 billion by the mid-2030s, lifting its cardiometabolic and respiratory outlook to $20 billion and infectious disease to $15 billion. Shares fell 1.2% to $109.19. Johnson & Johnson rose 2.6%, Eli Lilly gained 1.6%, and Pfizer slipped 0.8%. Merck said its pipeline could offset Keytruda’s loss of exclusivity by 2026.
13 January 2026
··
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck shares fell 1.1% to $109.27 Monday amid speculation over a possible $28–32 billion acquisition of Revolution Medicines, though no deal has been finalized. The SPDR S&P Biotech ETF dropped 2.1%. Analysts estimate Revolution’s RAS inhibitor drugs could generate over $10 billion in sales by 2035. Merck also faces a potential $2 billion annual revenue hit after U.S. vaccine schedule changes affecting Gardasil and RotaTeq.
12 January 2026
··
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck shares fell 0.4% to $110.53 Friday as reports surfaced of talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped 10.7% on the speculation. The Wall Street Journal and Financial Times said the deal would be among the largest pre-commercial biotech acquisitions. Investors await updates at the JPMorgan Healthcare Conference on Monday.
11 January 2026
···
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck shares fell 0.4% to $110.53 Friday after reports it is in talks to acquire Revolution Medicines for $28–32 billion. Revolution shares jumped in after-hours trading. The Financial Times said negotiations are ongoing, with no final deal yet. Investors are watching Merck’s appearance at the J.P. Morgan Healthcare Conference on Jan. 12.
10 January 2026
··
Cisco (CSCO) stock in focus as Supreme Court takes up Falun Gong lawsuit appeal

Cisco (CSCO) stock in focus as Supreme Court takes up Falun Gong lawsuit appeal

Cisco Systems shares slipped 0.1% to $73.88 after the U.S. Supreme Court agreed to hear its appeal in a lawsuit alleging the company aided China’s surveillance of Falun Gong practitioners. The case centers on whether U.S. law allows “aiding and abetting” claims against corporations for overseas abuses. Cisco denies wrongdoing and welcomed the court’s review. The company will report quarterly earnings on Feb. 11.
10 January 2026
·····
1 2 3 4 5 … 8

Stock Market Today

  • IonQ Soars 755% Revenue Growth, Expands into Satellite Networking
    May 21, 2026, 7:35 AM EDT. IonQ reported a 755% year-over-year revenue increase after shifting to a full-stack quantum computing model. The firm also announced expansion into satellite networking, signaling broader applications for its technology. This growth and diversification led to a rating upgrade, positioning IonQ as a standout quantum stock with notable upside potential and distinct risks.

Latest articles

Quantum Stocks Surge on $2 Billion Play; IonQ Faces Next Hurdle

Quantum Stocks Surge on $2 Billion Play; IonQ Faces Next Hurdle

21 May 2026
IonQ shares jumped 8% in premarket trading Thursday to $52.47 after the U.S. announced $2 billion in quantum-computing grants, though IonQ was not among the recipients. The company recently reported first-quarter revenue of $64.7 million, up 755% year-over-year, and raised its 2026 revenue outlook to $260–$270 million. SkyWater shareholders approved IonQ’s merger, pending regulatory approval.
Rigetti Shares Rally on U.S. Quantum Funding as Debate Over Value Returns

Rigetti Shares Rally on U.S. Quantum Funding as Debate Over Value Returns

21 May 2026
Rigetti Computing shares jumped 13.2% in premarket trading Thursday after reports the Trump administration will award $2 billion in grants to nine quantum-computing firms, including $100 million for Rigetti. The company reported Q1 revenue of $4.4 million and an operating loss of $26 million. Shares closed Wednesday at $16.88, quoted at $19.10 before the market opened.
VIDA Global Stock Draws Attention After AI Agent IPO

VIDA Global Stock Draws Attention After AI Agent IPO

21 May 2026
VIDA Global shares jumped 81.2% to close at $4.15 Wednesday, then traded at $4.97 pre-market Thursday after volatile early sessions on NYSE American. Founder and CEO Lyle Pratt bought 187,500 shares at the $4 IPO price, SEC filings showed. The company raised $15 million in its IPO last week, selling 3.75 million shares. VIDA reported 2025 revenue of $551,383 and a net loss of $2.9 million.
Go toTop